Magnetic iron oxide nanoparticles carrying PTEN gene to reverse cisplatin-resistance of A549/CDDP cell lines
To evaluate the feasibility of using magnetic iron oxide nanoparticle as wild PTEN gene carrier for transfection in vitro to reverse cisplatin-resistance of A549/CDDP cells, A549/CDDP cells were transfected with the wild PTEN gene expression plasmid (pGFP-PTEN) by magnetic iron nanoparticle and lipo2000. The transfection efficiency was detected by fluorescence microscope and flow cytometer. The expression levels of PTEN mRNA and protein were detected by reverse transcription polymerase chain reaction (RT-PCR) and immunocytochemistry analysis. The effect of PTEN transfection on cell cycle enhances the sensitivity of A549/CDDP to cisplatin and nanoparticle-mediated transfection has a higher efficiency than that of the liposome-mediated group. The apoptosis level was up-regulated in PTEN transfection group. The magnetic iron oxide nanoparticle could be used as one of the ideal gene carriers for PTEN gene delivery in vitro. PTEN can be an effective target for reversing cisplatin-resistance in lung cancer.
Key wordsmagnetic iron oxide nanoparticle liposome transfection lung cancer PTEN cisplatin-resistance
Unable to display preview. Download preview PDF.
- STECK P A, PERSHOUSE M A, JASSER S A, YUNG W K, LIN H, LIGON A H, LANGFORD L A, BAUMGARD M L, HATTIER T, DAVIS T, FRYE C, HU R, SWEDLUND B, TENG D H, TAVTIGIAN S V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers [J]. Nat Genet, 1997, 15(4): 356–362.CrossRefGoogle Scholar
- IWANAGA K, YANG Y, RASO M G, MA L, HANNA A E, THILAGANATHAN N, MOGHADDAM S, EVANS C M, LI H, CAI W W, SATO M, MINNA J D, WU H, CREIGHTON C J, DEMAYO F J, WISTUBA I I, KURIE J M. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer [J]. Cancer Res, 2008, 68(4): 1119–1127.CrossRefGoogle Scholar
- LIM W T, ZHANG W H, MILLER C R, WATTERS J W, GAO F, VISWANATHAN A, GOVINDAN R, MCLEOD H L. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer [J]. Oncol Rep, 2007, 17(4): 853–857.Google Scholar
- PERRONE F, LAMPIS A, ORSENIGO M, DI BARTOLOMEO M, GEVORGYAN A, LOSA M, FRATTINI M, RIVA C, ANDREOLA S, BAJETTA E, BERTARIO L, LEO E, PIEROTTI M A, PILOTTI S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients [J]. Ann Oncol, 2009, 20(1): 84–90.CrossRefGoogle Scholar
- ZHOU M, GU L, FINDLEY H W, JIANG R, WOODS W G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells [J]. Cancer Res, 2003, 63(19): 6357–6362.Google Scholar
- XIN J, YANG-DE Z, JI-WEI W, LI-HUA Z, PU Y, XU Z, YU H, LI Y. Preparation and characterization of fluorimetric folate-coupled chitosan nano-carrier [J]. Journal of Central South University: Science and Technology, 2010, 41(1): 161–165. (in Chinese)Google Scholar
- STEELMAN L S, NAVOLANIC P M, SOKOLOSKY M L, TAYLOR J R, LEHMANN B D, CHAPPELL W H, ABRAMS S L, WONG E W, STADELMAN K M, TERRIAN D M, LESLIE N R, MARTELLI A M, STIVALA F, LIBRA M, FRANKLIN R A, MCCUBREY J A. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors [J]. Oncogene, 2008, 27(29): 4086–4095.CrossRefGoogle Scholar
- WENG L P, SMITH W M, DAHIA P L, ZIEBOLD U, GIL E, LEES J A, ENG C. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death [J]. Cancer Res, 1999, 59(22): 5808–5814.Google Scholar
- BRUNI P, BOCCIA A, BALDASSARRE G, TRAPASSO F, SANTORO M, CHIAPPETTA G, FUSCO A, VIGLIETTO G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: Evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1 [J]. Oncogene, 2000. 19(28): 3146–3155.CrossRefGoogle Scholar